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sCTa b s t r a c t
Background and purpose: Comprehensive dosimetric analysis is required prior to the clinical implemen-
tation of pelvic MR-only sites, other than prostate, due to the limited number of site specific synthetic-CT
(sCT) dosimetric assessments in the literature. This study aims to provide a comprehensive assessment of
a deep learning-based, conditional generative adversarial network (cGAN) model for a large ano-rectal
cancer cohort. The following challenges were investigated; T2-SPACE MR sequences, patient data from
multiple centres and the impact of sex and cancer site on sCT quality.
Method: RT treatment position CT and T2-SPACE MR scans, from two centres, were collected for 90 ano-
rectal patients. A cGAN model trained using a focal loss function, was trained and tested on 46 and 44 CT-
MR ano-rectal datasets, paired using deformable registration, respectively. VMAT plans were created on
CT and recalculated on sCT. Dose differences and gamma indices assessed sCT dosimetric accuracy. A lin-
ear mixed effect (LME) model assessed the impact of centre, sex and cancer site.
Results: A mean PTV D95% dose difference of 0.1% (range: 0.5% to 0.7%) was found between CT and sCT.
All gamma index (1%/1 mm threshold) measurements were >99.0%. The LME model found the impact of
modality, cancer site, sex and centre was clinically insignificant (effect ranges: 0.4% and 0.3%). The mean
dose difference for all OAR constraints was 0.1%.
Conclusion: Focal loss cGAN models using T2-SPACE MR sequences from multiple centres can produce
generalisable, dosimetrically accurate sCTs for ano-rectal cancers.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 156 (2021) 23–28 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The potential benefits of magnetic resonance (MR)-only radio-
therapy treatment planning have been well documented, as has
the need to generate synthetic-CT (sCT) datasets to allow treat-
ment dose to be calculated [1,2]. Commercial sCT solutions are
available however a recent systematic review found that compre-
hensive dosimetric analysis is required prior to the clinical imple-
mentation of pelvic MR-only sites, other than prostate, due to the
limited number of site specific synthetic-CT dosimetric assess-
ments in the literature [3].
For pelvic MR-only sites, rectum and anus cancer sites have
increased complexity compared to prostate treatments as theyinclude male and female anatomy, greater tumour position varia-
tion and larger treatment volumes. To our knowledge, no studies
have assessed sCT dosimetric accuracy for anus treatments, while
a small number of studies have assessed rectum sCTs using a
mix of research and commercially available sCT solutions [4–9].
All dosimetric results were found to be clinically acceptable, how-
ever these studies only assessed small, <12, [6–9], or medium, 15–
20 [4,5], patient numbers and small numbers of female patients
(range 0–9).
The majority of pelvic sCT methods, including commercial prod-
ucts such as the Philips (Philips Healthcare, Ohio, USA) MRCAT
[10], use a T1 DIXON MR sequence as it provides good fat-
muscle-bone contrast and all previously reported rectum sCT stud-
ies used this sequence. However because T2 sequences are optimal
for ano-rectal GTV delineation [11–13], for a T1 DIXON sCT gener-
ation solution to be used clinically, a T2 sequence must also be
acquired. Requiring a second sequence reduces scanning efficiency
and can reduce the treatment accuracy by introducing inter-scan
Table 1
The MR and CT scan parameters for Centre A and centre B.
Centre A Centre B
MR Make & Model Siemens Espree 1.5 T Siemens Aera 1.5 T
Sequence 3D 3D
Resolution 1.4  1.4  1.5 mm 0.9  0.9  1.5 mm
Refocusing Flip Angle () 160 160
TR (ms) 1500 1600
TE (ms) 211 211
Bandwidth (Hz/px) 600 545
Echo train length 105 134
Field of View (Superior-Inferior) 216 mm Inferior: 2 cm inferior of genitalia
Superior: superior aspect of L5 vertebra or greater as required
Field of View (Axial) 450  450 mm2 450  450 mm2
CT Make & Model Siemens Sensation Open Philips Brilliance Big Bore
Resolution 1.1  1.1  3 mm 1.2  1.2  2 mm
kVp (kV) 120 120
X-ray Tube Current (mAs) 122 135
cGAN sCT generation for anorectal RTchanges including; motion, anatomical changes and registration
errors to the pathway. Ideally a single T2 sequence would be used
for pelvic sCT generation and target volume and organ delineation,
such as the T2-SPACE (Sampling Perfection with Application opti-
mised Contrasts using different flip angle Evolution) sequence
which is used within the Spectronic Medical AB (Helsingborg, Swe-
den) commercial prostate solution [14]. Additionally, only one of
these rectal sCT studies, Maspero [6], applies a deep learning
approach to sCT generation which are hypothesised to providing
more image contrast and detail within the sCT [15–17].
Here, we comprehensively assess a conditional generative
adversarial network (cGAN) sCT model, with a focal loss function
designed to enhance performance in the hard to predict bone
region. Absolute and dosimetric performance of this cGAN sCT
model is quantified for a large ano-rectal cohort, to give confidence
that ano-rectal sCT generation can be successful and is viable for
clinical use, where clinical acceptability is considered to be a dosi-
metric difference of ±2% [18]. This work addresses a number of
challenges to sCT generation including; the use of a routine T2-
SPACE MR sequence for sCT generation, the utilisation of patient
data from multiple centres and the impact of male vs. female anat-
omy and of cancer site, anal vs. rectal, on the sCT output, whilst
simultaneously addressing the persistent issue of poor cortical
bone density estimation.Method
Data acquisition
This study is part of a wider MR-only radiotherapy study: ‘‘Mri-
only treAtmeNT planning for Anal and Rectal cAncer radiotherapY”
(MANTA-RAY), research ethics committee (REC) reference: 18/
LO/1298, ISRCTN Registry: ISRCTN82734641, funded by the
National Institute for Health Research (NIHR): ICA-CDRF-2017-
03-005). Paired CT and MR datasets were collected from 90 ano-
rectal patients (73 rectum, 17 anus and 54 male, 36 female) from
two centres (37 from centre A, 53 from centre B) who were due
to undergo radical VMAT external beam radiotherapy and had no
contraindications to MRI. Exclusion criteria included patients with
artificial hips, and contra-indications to MRI, and as a consequence
2 additional patients who had received MRIs were excluded from
this study. Both scans were acquired in the radiotherapy treatment
position with matched bladder filling and immobilisation. T2-
SPACE MR scan acquisition time varied with scan length with a
mean of 5 minutes 20 seconds per acquisition.24Radiotherapy planning CT scans and T2-SPACE MR scans were
acquired at both centres with the parameters shown in Table 1.
The mean time between CT and MR data acquisition was 7.9 days
(range: 0 to 43 days). MR scans were scheduled for a time when the
patient had a clinical appointment prior to or during their first two
weeks of treatment.
Clinical target volumes and organs at risk (OARs) (rectum; blad-
der and bowel cavity, anus; small bowel, bladder, femoral heads
and genitalia) were delineated on the CT as per our centres stan-
dard treatment protocol for each patient’s routine treatment prior
to being utilised for this study.sCT model and pre-processing
The paired CT-MR datasets of 46 rectum patients were used to
train the sCT model, 22 from centre A, 24 from centre B and 32
male, 14 female. The data was pre-processed by registering the
MR to CT with a deformable registration, using patient external
and bladder structures as ‘‘controlling ROIs”, before being resam-
pled to the CT frame of reference in Raystation 8b (RaySearch Lab-
oratories, Stockholm, Sweden). All CT & MR voxels outside the
patient external contour were set to an intensity of 1024 and 0
respectively, using the patient external contour generated on each
individual dataset. Only image slices with both CT and MR data
were used to ensure the data was accurately paired. No gas within
the patient external was masked on CT or MR in the training
cohort.
The cGAN used a novel focal loss function and was trained for
170 epochs on a Tesla K-80 (Nvidia, California, USA) GPU including
the use of augmentation, A fuller description of the cGAN model
and rationale for its use can be seen in appendix A.Test data
CT and MR data for 44 patients; 15 rectum from centre A (7
male, 8 female), 17 anus (9 male, 8 female) and 12 rectum (6 male,
6 female) from centre B, were used as test data. Test MR datasets
were registered to the CT and masked using the same process as
for the training data. Deformable registration was chosen for the
test data as it removed the majority of inter-scan patient position
differences between the CT and MR scans. The sCT data (DIR sCT)
were generated using the model described above in section 2.2.
The DIR sCTs were imported into Raystation 8b and were inher-
ently registered to the CT. New patient external contours were gen-
erated for each sCT, all other target volumes and OARs were copied
Fig. 1. Matched T2-SPACE MR (left), CT (middle) and sCT (right) slices from an anal cancer patient, where the CT and MR have been deformably registered prior to sCT
generation.
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dataset, using the standard tool within Raystation 8b. All bowel
gas was masked for CT and sCT datasets at a threshold of 200
HU and set to water density (1 g/cm3) to ensure consistency with
the methodology of previous rectal sCT studies [4–6].
A second testing dataset was generated, where the MR data was
registered rigidly, rather than using deformable registration as pre-
viously, to the CT data prior to sCT generation (RIR sCT). Masking
was carried out using the rigidly registered MR patient external.
Analysis was carried out on both data sets.Assessing sCT quality
HU analysis
Hounsfield Unit (HU) accuracy was determined by computing
the mean absolute error (MAE) and mean error (ME) in the (over-
lap) patient external volume and also in a region thresholded to25>150 HU on each CT dataset to represent bony anatomy. Thirteen
patients with bowel CT contrast or metal implants of any type
were excluded from this specific analysis.Plan generation & dosimetric analysis
VMAT plans, following departmental clinical protocols, were
created and optimised for each patient’s CT scan, clinical treatment
target volumes and OARs, in Raystation 8b, using the collapsed
cone photon algorithm on a dose grid of 3  3  3 mm3. Rectum
plans were prescribed as either 45 Gy in 25 fractions or 25 Gy in
5 fractions to the PTV chosen according to their clinical treatment
and anus plans were a simultaneous integrated boost technique
with 53.2 Gy and 40 Gy in 28 fractions prescribed to the primary
and elective PTVs respectively. Each CT plan was subsequently
recalculated, without reoptimisation, on the sCT.
Dosimetric differences between doses calculated on the CTs and
sCTs were assessed through primary PTV dose statistics, D95%,
cGAN sCT generation for anorectal RTD50% and D2%, for each plan. Global dose gamma index calcula-
tions between the CT and sCT were also performed for 3%/3 mm,
2%/2 mm and 1%/1 mm thresholds. The gamma indices were calcu-
lated using a region of interest defined as voxels within a dose
threshold of 20% of the target prescription dose. For anus treat-
ments, where an elective nodal PTV (PTVE) was also present and
prescribed 40 Gy, the PTVE D95% differences were also assessed
as a further measure of accuracy.
OAR dose statistics were assessed for the 29 patients from cen-
tre B to establish the dosimetric accuracy of treatment plan calcu-
lations away from the primary PTV. Only patients from centre B
were assessed as this ensured consistency in the approach, includ-
ing scan field of view being sufficient for all OARs, and all OAR con-
tours being delineated using the same clinical protocol. Assessed
OARs were bladder and bowel cavity for rectum plans and bladder,
small bowel, femoral heads and genitalia for anus plans. The clin-
ical protocol OAR constraint statistics were collected for CT and DIR
sCT plans, the absolute differences were calculated between CT and
sCT and compared as a percentage of the constraint tolerance level.Fig. 2. All (circle) and mean (diamond) PTV dose differences and gamma indices for
the DIR and RIR sCTs, where dose differences are calculated as a percentage of the
prescription dose.Statistical analysis
A linear mixed effect (LME) model was utilised to quantify the
statistical significance of dosimetric differences and constrain the
effect within 95% confidence intervals between modalities, CT
and sCT. The model also allowed the quantification of dosimetric
differences of secondary variables within the dataset including;
treating centre, patient sex and cancer site. The LME model used:
dose (normalised by prescription dose) as the dependant variable;
modality, sex, treating centre, cancer site and dose statistic (D95%,
D50%, D2%) as fixed variables; and patient as a random variable.Results
Fig. 1. shows matched T2-SPACE MR (left), CT (middle) and sCT
(right) slices from an anal cancer patient, where the CT and MR
have been deformably registered prior to sCT generation. For DIR
sCTs, mean ME of 0.4 (range: 7.8 to 12.4) HU was observed across
the analysed cohort, with mean MAE of 35.1 (range: 27.2 to 40.3)
HU. Bone showed a mean ME of 95.5 (range: 290 to 0.6)
HU. For RIR sCT, mean MAE, ME, Bone MAE and Bone ME were
44.5, 0.8, 250.2 and 142.1 HU respectively.
Dosimetric DIR sCT results are shown in Table 2 and Fig. 2. All
dose differences were found to be less than ±0.8% (Fig. 2). All
gamma indices at 1%/1 mm were greater than 99.0%. For anus
treatments the mean dose difference for PTVE D95% was 0.1%Table 2
DIR test data dose differences and gamma indices for DIR sCTs vs. CTs for all patients and su
of the prescription dose.
Number of Patients Dose
constraint
Dose difference (%) mean (S.D) [ran
All 44 D95% 0.1 (0.2) [0.5 to 0.7]
D50% 0.1 (0.3) [0.6 to 0.6]
D2% 0.1 (0.3) [0.6 to 0.7]
Rectum 27 D95% 0.1 (0.3) [0.5 to 0.7]
D50% 0.1 (0.3) [0.6 to 0.6]
D2% 0.1 (0.3) [0.6 to 0.6]
Anus 17 D95% 0.1 (0.2) [0.2 to 0.5]
D50% 0.2 (0.2) [0.2 to 0.5]
D2% 0.1 (0.2) [0.2 to 0.5]
Male 22 D95% 0.1 (0.2) [0.2 to 0.5]
D50% 0.1 (0.2) [0.2 to 0.5]
D2% 0.1 (0.2) [0.2 to 0.4]
Female 22 D95% 0.1 (0.3) [0.5 to 0.7]
D50% 0.1 (0.3) [0.6 to 0.6]
D2 0.1 (0.4) [0.6 to 0.7]
26(SD: 0.1%, range: 0.1% to 0.3%). OAR dosimetric differences
(Table 4) were found to be small with a mean difference of 0.1%,
(S.D: 0.6%) of the constraint tolerances over all organ measures.
The Rigid sCT mean dose difference was similar to the DIR sCT
mean dose difference (0.1% vs. 0.1%), however considerably more
variability was seen for Rigid sCTs.
The LME model found a 95% confidence interval range in dose
difference of 0.0% to 0.2% between CT and DIR sCT (Table 3). No sig-
nificant differences in dose were found between treating centre,
cancer site; anal or rectal, or sex, with the maximum effect sizes
within 95% confidence intervals showing no clinically significant
differences (considered to be <±2%) [18].
Discussion
This study is the first to assess sCT dosimetric accuracy for anal
cancer treatments and is the largest known patient cohort for rec-
tal cancer treatments. We found that focal loss driven cGAN-based
sCT generation using T2-SPACE MR sequences for ano-rectal can-
cers achieved excellent sCT quality. Comparing the RIR sCT cGAN
results from this study to Maspero et. al. [6], who achieved MAE
of 62 HU, our method shows an absolute improvement of ~18
HU. This represents a 40% reduction in HU error across the cohort.b-categories; cancer site and sex where dose differences are calculated as a percentage
ge] Gamma Index – mean (S.D) [range]
3%/3 mm 2%/2 mm 1%/1 mm
100 (0.1) [99.8 to 100] 99.8 (0.1) [99.3 to 100] 99.5 (0.2) [99.0 to 100]
100 (0.0) [99.8 to 100] 99.8 (0.1) [99.5 to 100] 99.5 (0.2) [99.0 to 100]
99.9 (0.1) [99.8 to 100] 99.7 (0.2) [99.3 to 100] 99.4 (0.2) [99.0 to 99.9]
99.9 (0.1) [99.8 to 100] 99.8 (0.1) [99.5 to 100] 99.5 (0.2) [99.1 to 99.8]
100 (0.0) [99.8 to 100] 99.8 (0.2) [99.3 to 100] 99.4 (0.3) [99.0 to 100]
Table 3
Linear mixed effects model coefficients and 95% confidence intervals, where dose









Modality (CT vs. sCT) 0.1 0.0 0.2
Hospital (centre A vs centre B) 0.1 0.4 0.1
Site (rectal cancer vs anal cancer) 0 0.2 0.3
Sex (male vs female) 0 0.2 0.1
D. Bird, M.G. Nix, H. McCallum et al. Radiotherapy and Oncology 156 (2021) 23–28The DIR sCT dosimetric differences to CT (mean +0.1%) and
gamma index analysis findings (all patients >99.0% at 1%/1 mm
threshold) show an excellent level of agreement. These results sug-
gest the sCT solution is clinically acceptable, while the large testing
cohort size which supports confidence that this result is represen-
tative of the patient population. The LME model dosimetric differ-
ence effect size (0.1%) is also in line with previously published
studies (±0.3%) [4–9]. The dosimetric assessment of OAR con-
straints also found clinically acceptable agreement between sCT
and CT (mean difference: 0.1%) suggesting that clinically sufficient
sCT dosimetric accuracy extends throughout the entire sCT dataset.
These results are also in line with previously reported OAR dose
statistics for rectum sCT datasets (mean dose difference: ~0.6%)
[5,8].
The assessment of rigidly registered sCTs to CT is a comparison
of the ‘‘true” MR-only planning sCT, where no image augmentation
has occurred, however it also introduces unpredictable inter-scan
patient body changes which will impact the dosimetric difference
to CT. The mean sCT dose difference of 0.1% vs. CT is more than
clinically acceptable, but substantially greater range in the dose
difference was seen compared to the DIR sCTs (Fig. 2). This sug-
gests the underlying systematic sCT to CT dose difference is similar
to the DIR data, but being masked by the larger random error of
these less similar datasets. This larger range of dosimetric differ-
ence across the rigid cohort can be explained by the time differ-
ences between CT and MR in the test cohort which can cause
changes in patient anatomy. This was a limitation of the study that
was required to enable successful data collection. A potential issue
with using DIR datasets is that the deformable registration may
mask an inherent lack of skin tissue visualisation which can occur
with MR sequences by matching the CT and MR skin surfaces so
any dosimetric differences caused by the inherent skin visualisa-
tion will not be represented in the DIR data. However, these differ-
ences would be represented in the RIR dataset results and we
found the maximum systematic dosimetric impact between CT
and MR was 0.1%.
This study suggests that there is no detriment to the sCT image
quality or dosimetric accuracy by using T2-SPACE sequences when
used in combination with a focal loss GAN-based deep learning
model. This is of benefit to improving the efficiency and accuracy
of pelvic MR-only planning as it allows a single scan to be usedTable 4
OAR relative dose differences between DIR sCT and CT plans for each organ constraint for e
sCT as a percentage of the constraint tolerance.
OAR Dose constraint
Rectum Bowel Cavity V30/V18
Bladder V35Gy/V21Gy
Anus Bladder D35%
Small Bowel D150 cc
Femoral Heads D35%
Genitalia D50%
27for sCT generation and target volume and OAR delineation. Only
using one sequence reduces MR scanning time, making the scan
more tolerable for patients and reducing costs and eliminates sys-
tematic registration errors between multiple required MRI scans
caused by patient position changes. Therefore it would be benefi-
cial if more commercially available pelvic solutions utilised T2
sequences rather than T1 sequences for pelvic sCT generation.
The LME model allowed the assessment of the impact of using
data from multiple centres by assessing the 95% confidence inter-
val values of the effect of the associated variables. The small range
of effect (-0.4 to +0.1%) between sCTs from centres A and B sug-
gests our cGAN method is capable of producing a generalisable
solution for use at multiple centres, in the case that some data from
each centre is used in training data. Analogous to this is the situa-
tion where a single centre has data from multiple sources – for
example multiple MR scanners all with slightly different sequence
parameters. This is a beneficial feature as it could allow centres to
pool data for sCT model generation making the generation of sCT
models more feasible for smaller centres where the required data
is harder to collect. We expected differences between sCTs from
different centres due to differences in the input MR scans where
there was a 3-fold scaling factor and therefore quantisation differ-
ences in the low intensity areas of the images (air, bone and mus-
cle) between MRs from centre A and centre B (a further description
of the quantisation difference can be seen in appendix A). However,
our results are evidence that this model can handle bimodal input
data and produce consistent results.
GAN methods such as ours and Maspero [6] do not appear to
provide a significant dosimetric improvement compared to other
methods [4,5], however in this case it has allowed a more diverse,
less-optimal dataset to be utilised to produce a robust, generalis-
able solution. The HU values of bone are significantly better repre-
sented with a focal loss cGAN. This improved bone representation
may improve the use of sCTs for CBCT patient treatment position-
ing and it would be beneficial to investigate this further. A limita-
tion of this study is the use of only one MRI vendor, although
different scanner models, at both centres which limits the intensity
variability between the matched sequences. It would be of benefit
to assess this sCT generation model on a wider variety of input
data, including more centres and scanner vendors as this would
allow a greater assessment of the model’s generalisability.
There are some limitations to generating sCT datasets using a
cGAN as in this study, and these relate to training cohort require-
ments. Training cohorts need to be sufficiently large to produce
generalisable and robust results and have accurate registration
between CT and MR. This can mean a large cohort of patient data
needs to be prospectively acquired which takes time. An additional
limitation of cGANs is that once the model is trained, input data for
generating sCTs is fixed such that parameters need to remain the
same as for the training data. This requires users to be confident
regarding their future cGAN model use and MR-only pathways
prior to use.
This study shows that T2-SPACE MR sequences from multiple
centres can produce generalisable, dosimetrically accurate, sCTsach cancer site. Mean, S.D. and range are calculated as the difference between CT and
Tolerance Dose difference (%) mean (S.D) [Range]
250 cc 0.1 (0.4) [0.5 to 1.0]
45% 0.0 (0.4) [0.9 to 0.6]
45 Gy 0.1 (0.1) [0.1 to 0.2]
50 Gy 0.3 (0.4) [0.5 to 0.9]
40 Gy 0.0 (0.1) [0.1 to 0.3]
35 Gy 0.0 (0.2) [0.6 to 0.4]
cGAN sCT generation for anorectal RTwith low HU errors, for a large cohort of ano-rectal cancer patients
and that a single T2 MR sequence can be used for both target and
OAR delineation and sCT generation. Dosimetric differences were
minimal and clinically insignificant for both PTVs and OARs. The
model, which employed focal loss with a cGAN proved robust to
differences in input data such as treating centre, cancer site and
patient sex.
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